Brain germinoma

Summary

Brain germinoma (MONDO:0002214) is a disease and 1 clinical trial. Top therapeutic interventions include bleomycin and cyclophosphamide anhydrous. A subtype of brain cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	brain germinoma
Mondo ID	MONDO:0002214
DOID	DOID:2127
NCIT	C6284
UMLS	C1332606
MedGen	231457
GARD	0023086
Anatomy (UBERON)	UBERON:0000955
Is cancer (heuristic)	no

Also known as: brain germinoma (disease) · germinoma of brain · germinoma of the brain · intracranial germinoma

Disease family

This is a subtype of brain cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › brain cancer › brain germinoma

Related subtypes (8): supratentorial cancer, brain sarcoma, cerebral ventricle cancer, infratentorial cancer, intracranial primitive neuroectodermal tumor, brain glioma, cancer of cerebellum, metastatic malignant neoplasm in the brain

Subtypes (2): pineal region germinoma, childhood brain germinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02782754	PHASE2	UNKNOWN	Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BLEOMYCIN	4	1
CYCLOPHOSPHAMIDE ANHYDROUS	4	1